Top Markets
Coin of the day
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

LBPH
Pozycja w akcjach #8563
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Cena akcji
$59.98
Ostatnia synchronizacja: 2024-12-13
Kapitalizacja rynkowa
$1.22B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Longboard Pharmaceuticals, Inc. (LBPH)

Kategoria

EPS dla Longboard Pharmaceuticals, Inc. (LBPH)
EPS na dzień September 2024 TTM: $-2.24
Według najnowszych raportów finansowych i ceny akcji firmy Longboard Pharmaceuticals, Inc., obecny EPS (TTM) wynosi $-2.24. Na koniec roku 2022 firma miała EPS w wysokości $-2.51, wzrost w porównaniu do do EPS z roku 2021, który wynosił $-1.62.
Historia EPS dla Longboard Pharmaceuticals, Inc. od 2020 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-2.24 -6.28%
2023 $-2.39 -4.78%
2022 $-2.51 54.94%
2021 $-1.62 97.56%
2020 $-0.82 0.00%
EPS dla podobnych firm lub konkurentów
Firma EPS Różnica w EPS Kraj
$17.32 -873.21%
US
$27.74 -1,338.39%
NL
$-5.29 136.16%
AU
$-7.98 256.25%
US
- -
CH